Clinical Prior Authorization Guidelines - UnitedHealthcare Community Plan of Texas
UnitedHealthcare Community Plan’s Clinical Pharmacy Program Guidelines are updated on an ongoing basis by our Pharmacy and Therapeutics Committee. Our changes reflect recent developments in pharmaceutical health care so we’re aligned with national treatment standards.
Clinical Pharmacy Prior Authorization Guidelines
CHIP Clinical Prior Authorization Guidelines
The following clinical prior authorization guidelines apply to CHIP plans.
- Acthar Gel
- Allergen Extracts
- Amantadine Extended-Release Agents
- Androgenic Agents
- Antiseizure Agents Diacomit, Epidiolex and Fintepla
- Appetite Suppressant Agents
- Arikayce
- Buprenorphine Agents
- CNS Stimulants
- Cough and Cold Medications
- Cytokine and CAM Antagonists
- Cystic Fibrosis Agents
- Diclofenac
- Dopamine Agonists
- Doxylamine/Pyridoxine
- Duplicate Therapy
- Enzymes
- Erythropoiesis-Stimulating Agents
- Evrysdi (Risdiplam)
- Gabapentin
- Gattex
- Gonadotropin Releasing Hormone (GnRH)
- Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
- Growth Hormones
- Hemady (Dexamethasone)
- Hereditary Angioedema (HAE)
- Hormonal Therapy Agents
- Hyperlipidemia Agents
- Immunomodulator Agents for Dry Eye
- Inhaled Antibiotics
- Lyrica (pregabalin)
- Monoclonal Antibody Agents
- Multiple Sclerosis Agents
- Nuplazid
- Omega-3 Fatty Acids
- Orilissa
- Oxervate (cenegermin-bkbj)
- Oxybate
- Phosphate Binders
- Pulmonary Arterial Hypertension (PAH)
- Ranexa
- Sickle Cell Agents
- Sphingosine 1-phosphate (S1P) Receptor Modulators
- Synagis (palivizumab)
- Topical Immunomodulators
- Transthyretin Agents
- Veozah (Fezolinetant)
- Xifaxan (rifaximin)
STAR, STAR Kids, STAR+PLUS Clinical Prior Authorization Guidelines
- Go here to view the most recent Texas Medicaid Preferred Drug List (PDL) and Prior Authorization Criteria (PA). PA Criteria for non-preferred drugs and additional details are on the right side of the PDL chart.
- To view the clinical prior authorizations approved for use in Medicaid managed care by the Vendor Drug Program.
- The Pharmacy Clinical Prior Authorization Assistance Chart (PDF) shows the prior authorization UnitedHealthcare uses (as well as by other Managed Care Organizations and those used for traditional Medicaid). This chart is updated quarterly.
These guidelines apply to STAR, STAR Kids and STAR+PLUS plans.
- Acthar Gel
- Altabax (retapamulin)
- Allergen Extracts
- Amantadine Extended-Release Agents
- Androgenic Agents
- Antiseizure Agents, Diacomit, Epidiolex and Fintepla
- Appetite Suppressant Agents
- Arikayce
- Buprenorphine Agents
- Calcitonin Gene-Related Peptide Receptor (CGRP) Antagonists, Acute
- Calcitonin Gene-Related Peptide Receptor (CGRP) Antagonists, Chronic
- Central Nervous System Stimulants
- Cough and Cold Medications
- Copaxone (glatiramer)
- Cytokine and CAM Antagonists
- Cystic Fibrosis Agents
- Diclofenac 3% Gel, Diclofenac 1.5% and 2% Topical Solution
- Dopamine Agonists
- Doxylamine/Pyridoxine
- Duplicate Therapy
- Emflaza
- Enzymes
- Epidiolex
- Erythropoiesis-Stimulating Agents
- Evrysdi (Risdiplam)
- Gabapentin Agents
- Gattex
- Gaucher's Disease Agents
- GI Motility Agents
- Glatiramer Acetate Injection
- Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
- Gonadotropin Releasing Hormone (GnRH) Receptor Antagonists
- Growth Hormones
- Hemady (Dexamethasone)
- Hereditary Angioedema (HAE)
- Hormonal Therapy Agents
- Hyperlipidemia Agents
- Imiquimod
- Immunomodulator Agents for Dry Eye
- Increlex (mecasermin)
- Inhaled Antibiotics
- Lidocaine Patches
- Lyrica
- Monoclonal Antibody Agents
- Multiple Sclerosis Agents
- Nitazoxanide (formerly Alinia)
- Nuedexta (dextromethorphan / quinidine)
- Nuplazid
- Omega-3 Fatty Acids (formerly Lovaza)
- Oriahnn (Elagolix, Estradiol and Norethindrone)
- Orilissa
- Oxervate (cenegermin-bkbj)
- Oxybate
- Phosphate Binders
- Phosphodiesterase 5 (PDE5) Inhibitors
- Promethazine/Promethazine Containing Products
- Pulmonary Arterial Hypertension (PAH)
- Ranexa
- Savella (milnacipran)
- Sickle Cell Agents
- Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
- Sphingosine 1-phosphate (S1P) Receptor Modulators
- Symlin (pramlintide Acetate)
- Synagis
- Topical Immunomodulators
- Transthyretin Agents
- Urea Cycle Disorder Agents
- Veozah (Fezolinetant)
- Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors
- Wakix (Pitolisant)
- Xifaxan (rifaximin)
- Zelboraf (vemurafenib)